UA89201C2 - Энантиомеры выбранных конденсированных пиримидонов и их применение для лечения и профилактики злокачественного новообразования - Google Patents

Энантиомеры выбранных конденсированных пиримидонов и их применение для лечения и профилактики злокачественного новообразования

Info

Publication number
UA89201C2
UA89201C2 UAA200702661A UAA200702661A UA89201C2 UA 89201 C2 UA89201 C2 UA 89201C2 UA A200702661 A UAA200702661 A UA A200702661A UA A200702661 A UAA200702661 A UA A200702661A UA 89201 C2 UA89201 C2 UA 89201C2
Authority
UA
Ukraine
Prior art keywords
cancer
treatment
enantiomers
prevention
selected fused
Prior art date
Application number
UAA200702661A
Other languages
English (en)
Ukrainian (uk)
Inventor
Брайан Акила
Майкл Говард Блок
Одри ДЕЙВИС
Джеяхандран Эжутхачан
Тимоти Понц
Дениэл Джон Расселл
Марие-Елена Теоклитоу
СяоЛань Чжен
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37904998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA89201(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of UA89201C2 publication Critical patent/UA89201C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Данное изобретение касается новых соединений, которые имеют структурную формулу (И), (I)и их фармацевтических композиций и способов их применения.Эти новые соединения обеспечивают лечение или профилактику злокачественного новообразования.
UAA200702661A 2004-08-18 2005-08-16 Энантиомеры выбранных конденсированных пиримидонов и их применение для лечения и профилактики злокачественного новообразования UA89201C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60236604P 2004-08-18 2004-08-18

Publications (1)

Publication Number Publication Date
UA89201C2 true UA89201C2 (ru) 2010-01-11

Family

ID=37904998

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200702661A UA89201C2 (ru) 2004-08-18 2005-08-16 Энантиомеры выбранных конденсированных пиримидонов и их применение для лечения и профилактики злокачественного новообразования

Country Status (18)

Country Link
US (3) US20080293744A1 (ru)
EP (1) EP1781674A1 (ru)
JP (1) JP2008509977A (ru)
KR (1) KR20070046176A (ru)
CN (1) CN101027309B (ru)
AU (1) AU2005273705B8 (ru)
BR (1) BRPI0514390A (ru)
CA (1) CA2575188A1 (ru)
IL (1) IL180810A0 (ru)
MX (1) MX2007001953A (ru)
MY (1) MY141233A (ru)
NO (1) NO20071005L (ru)
RU (1) RU2447077C2 (ru)
SA (1) SA05260258B1 (ru)
TW (1) TW200616977A (ru)
UA (1) UA89201C2 (ru)
UY (1) UY29070A1 (ru)
ZA (1) ZA200701082B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20125635B (en) * 2007-11-13 2012-09-10 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
SI2448938T1 (sl) 2009-06-29 2014-08-29 Incyte Corporation Experimental Station Pirimidinoni kot zaviralci pi3k
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclic amines as inhibitors of PI3K
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PL3052485T3 (pl) 2013-10-04 2022-02-28 Infinity Pharmaceuticals, Inc. Związki heterocykliczne i ich zastosowania
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
TWI748941B (zh) 2015-02-27 2021-12-11 美商英塞特公司 Ｐｉ３ｋ抑制劑之鹽及製備方法
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2024103067A1 (en) * 2022-11-10 2024-05-16 Ribometrix, Inc. COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792767A (en) 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
DK0888359T3 (da) 1996-03-11 2002-08-12 Syngenta Participations Ag Pyrimidin-4-on-derivat som pesticid
SI1140941T1 (en) 1998-12-23 2005-04-30 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor xa inhibitors
WO2001019800A2 (en) 1999-09-16 2001-03-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
EP1686120A3 (en) 1999-10-27 2007-05-30 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU2001297717B2 (en) 2000-12-11 2006-02-23 Amgen Inc. CXCR3 antagonists
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
IL158083A0 (en) 2001-03-29 2004-03-28 Bristol Myers Squibb Co A PHARMACEUTICAL COMPOSITION CONTAINING AN Eg5 PROTEIN INHIBITOR
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
EP1383771A1 (en) 2001-04-20 2004-01-28 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003043995A1 (en) * 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
EP1465896A4 (en) * 2001-12-06 2006-01-11 Merck & Co Inc MITOTIC INHIBITORS OF KINESIN
CA2468266A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Substituted bicyclic pyrimidinones as a mitotic kinesin ksp inhibitors
JP4467979B2 (ja) * 2001-12-06 2010-05-26 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
JP4464136B2 (ja) * 2001-12-06 2010-05-19 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害薬
WO2003050064A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2005529076A (ja) 2002-02-15 2005-09-29 サイトキネティクス・インコーポレーテッド キナゾリノンの合成
JP4664597B2 (ja) * 2002-04-17 2011-04-06 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
MXPA04011074A (es) 2002-05-09 2005-06-08 Cytokinetics Inc Compuestos de pirimidinona, composiciones y metodos.
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
EP1513820A4 (en) * 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1509507A4 (en) 2002-05-23 2006-09-13 Merck & Co Inc INHIBITORS OF MITOTIC KINESIN
US20050203110A1 (en) 2002-05-23 2005-09-15 Coleman Paul J. Mitotic kinesin inhibitors
AU2003236527A1 (en) 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003252025A1 (en) 2002-07-17 2004-02-02 Cytokinetics, Inc. Compounds, compositions, and methods
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
JP2005536553A (ja) 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2004034972A2 (en) 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
BR0315247A (pt) 2002-10-11 2005-08-30 Cytokinetics Inc Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit
JP2006502230A (ja) 2002-10-11 2006-01-19 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2004064741A2 (en) 2003-01-17 2004-08-05 Cytokinetics Inc. Compounds, compositions, and methods
US20060270689A1 (en) * 2003-03-07 2006-11-30 Astrazeneca Ab Novel Fused Heterocycles and Uses Thereof
WO2006018628A1 (en) 2003-03-07 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
WO2004091547A2 (en) 2003-04-10 2004-10-28 Cytokinetics, Inc Compounds, compositions, and methods
US20080021079A1 (en) 2003-05-07 2008-01-24 Han-Jie Zhou Compounds, Compositions, and Methods
WO2005013888A2 (en) 2003-05-14 2005-02-17 Cytokinetics, Inc. Compounds, compositions and methods
EP1622878A4 (en) 2003-05-15 2008-04-09 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
ES2339862T3 (es) 2003-06-20 2010-05-26 Novartis Vaccines And Diagnostics, Inc. Compuestos de piridino 1,2-a-pirimidin-4-ona como agentes anticancerosos.
WO2005042697A2 (en) 2003-10-06 2005-05-12 Cytokinetics, Inc. Compounds, compositions and methods
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
CN1886384A (zh) 2003-11-25 2006-12-27 希龙公司 喹唑酮化合物作为抗癌药剂
US7439254B2 (en) 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
JP4895220B2 (ja) 2004-04-06 2012-03-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キネシン有糸分裂インヒビター
DK1753723T3 (da) 2004-05-21 2008-10-20 Novartis Vaccines & Diagnostic Substituerede quinolinderivater som mitotiske kinesininhibitorer
MXPA06014909A (es) 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
MX2007001954A (es) 2004-08-18 2007-05-09 Astrazeneca Ab Heterociclicos fusionados seleccionados y sus usos.
US20060041128A1 (en) 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
US8008335B2 (en) * 2004-10-19 2011-08-30 Novartis Vaccines And Diagnostics, Inc. Indole and benzimidazole derivatives

Also Published As

Publication number Publication date
MY141233A (en) 2010-03-31
TW200616977A (en) 2006-06-01
US20060041129A1 (en) 2006-02-23
US20080293744A1 (en) 2008-11-27
SA05260258B1 (ar) 2009-12-22
CA2575188A1 (en) 2006-02-23
AU2005273705B2 (en) 2009-12-10
IL180810A0 (en) 2007-06-03
CN101027309B (zh) 2010-10-27
RU2447077C2 (ru) 2012-04-10
US7498333B2 (en) 2009-03-03
ZA200701082B (en) 2008-07-30
RU2007109866A (ru) 2008-09-27
AU2005273705B8 (en) 2010-01-28
EP1781674A1 (en) 2007-05-09
US20090099210A1 (en) 2009-04-16
JP2008509977A (ja) 2008-04-03
CN101027309A (zh) 2007-08-29
BRPI0514390A (pt) 2008-06-10
NO20071005L (no) 2007-05-16
AU2005273705A1 (en) 2006-02-23
KR20070046176A (ko) 2007-05-02
UY29070A1 (es) 2006-03-31
MX2007001953A (es) 2007-05-09

Similar Documents

Publication Publication Date Title
UA89201C2 (ru) Энантиомеры выбранных конденсированных пиримидонов и их применение для лечения и профилактики злокачественного новообразования
IL260127B (en) mek inhibitors and methods of using them
MXPA05009885A (es) Nuevas triazolonas fusionadas y los usos de las mismas.
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
HK1113352A1 (en) Chemical compounds
HK1114375A1 (en) Chemical compounds
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TW200714604A (en) Substituted heterocycles and the uses thereof
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
TNSN06228A1 (en) Compounds and methods of use
EP2400847A4 (en) SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS
TW200738659A (en) Novel compounds
PL1809288T3 (pl) Zastosowanie pochodnych 1,4-bis-(3-aminoalkilo)piperazyny do leczenia chorób neurodegeneracyjnych
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
TW200736227A (en) New compounds III
MX2007001954A (es) Heterociclicos fusionados seleccionados y sus usos.
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
TW200720262A (en) Novel compounds ii
TW200510427A (en) Novel fused heterocycles and uses thereof
GB0407025D0 (en) Novel compounds
TNSN07300A1 (en) 1,3-thiazole-5-carboxamides useful as cancer chemotherapeutic agents
UA95260C2 (ru) Производное 4-(3-аминопиразол)пиримидина и его применение для лечения злокачественного новообразования
TW200505440A (en) Novel fused triazolones and the uses thereof